Published: Wed, August 02, 2017
Business | By Max Garcia

Pfizer, Inc. (PFE) to Issue Quarterly Dividend of $0.32 on September 1st

Pfizer, Inc. (PFE) to Issue Quarterly Dividend of $0.32 on September 1st

Shares of Pfizer, Inc. On the other side it is not a negative indicator for Investor portfolio value - when the price of a stock Investor owns moves down in value.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. D Orazio & Associates Inc. increased its stake in Pfizer by 0.5% in the fourth quarter. FMR LLC now owns 21,970,338 shares of the biopharmaceutical company's stock worth $713,596,000 after buying an additional 3,958,324 shares during the last quarter. Asset Planning Services Ltd. raised its position in Pfizer by 4.9% in the first quarter. Cable Hill Partners LLC boosted its position in Pfizer by 6.0% in the first quarter. Orrstown Financial Services Inc. raised its position in Pfizer by 23.0% in the first quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company's stock valued at $170,000 after buying an additional 28 shares during the last quarter.

In all, Pfizer reported earnings of $3.07 billion, or 51 cents per share, up from $2.05 billion, or 33 cents per share, a year earlier.

Lord Abbett & Company, which manages about $32.94B US Long portfolio, decreased its stake in Ulta Salon Cosmetcs & Frag I Com (NASDAQ:ULTA) by 59,225 shares to 82,060 shares, valued at $20.92M in 2016Q4, according to the filing. The stock has a 50 day moving average price of $33.38 and a 200-day moving average price of $33.25. The company has a market capitalization of $195.66 billion, a PE ratio of 27.597 and a beta of 1.01. The Switzerland-based Banque Pictet & Cie Sa has invested 0% in the stock. This is an increase of 113% compared to the average daily volume of 6,261 call options.

Pfizer Inc. (NYSE: PFE) reported second-quarter 2017 results before markets opened Tuesday.

On average, analysts polled by Thomson Reuters expected earnings of $0.66 per share on revenues of $13.08 billion for the quarter. In the same period a year ago, Pfizer posted EPS of $0.64 on revenues of $13.15 billion. Pfizer's revenue was down 1.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.64 EPS.

Pfizer has increased its dividend by an average of 7.7% per year over the last three years and has increased its dividend every year for the last 7 years.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be issued a dividend of $0.32 per share. The ex-dividend date is Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.86%.

COPYRIGHT VIOLATION WARNING: "Pfizer, Inc". Independent Portfolio Consultants reported 0.26% in Pfizer Inc. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of USA and global copyright legislation. The original version of this piece can be accessed at

Several analysts have issued reports on the stock. Morgan Stanley reaffirmed a "neutral" rating and set a $38.00 target price on shares of Pfizer in a report on Thursday, April 6th. BidaskClub cut shares of Pfizer from a "sell" rating to a "strong sell" rating in a research note on Thursday, July 13th. Finally, Cowen and Company set a $43.00 target price on Pfizer and gave the company a "buy" rating in a report on Monday, July 10th. Barclays PLC reiterated a "buy" rating and set a $38.00 price objective on shares of Pfizer in a research note on Wednesday, May 3rd.

Among 5 analysts covering ECN Capital Corp (TSE:ECN), 5 have Buy rating, 0 Sell and 0 Hold.

Pfizer Inc. (PFE) price is trading at a gap of -0.26% from an average price of last twenty days and standing at a distance of 0.60% away from it's an average price of recent fifty days. The stock of Pfizer Inc. The Firm is engaged in the discovery, development and manufacture of healthcare products. Pfizer's essential health segment, which sells older products that are mostly off patent, had sales drop 14 percent to $5.23 billion.

Like this: